Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain
(RBD) of the trimeric spike. Here, we characterized polyclonal immunoglobulin Gs (IgGs) …

In the ongoing coronavirus disease 2019 (COVID-19) pandemic, there remain unanswered
questions regarding the nature and significance of the humoral immune response toward …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2
on host cells is essential for viral entry. RBD is the dominant target for neutralizing …

The protective human antibody response to severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) focuses on the spike (S) protein, which decorates the virion surface and …

The COVID-19 pandemic is a major threat to global health for which there are only limited
medical countermeasures, and we lack a thorough understanding of mechanisms of …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight
into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response …

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …

Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-
CoV-2 infection is crucial for understanding immune protection and identifying targets for …